Scanlan Sean F. 4

What Happened

• Sean F. Scanlan, Chief Innovation Officer of Treace Medical Concepts, reported two disposals to cover tax liabilities related to equity awards (transaction code F). On 2026-03-08 he surrendered 401 shares and on 2026-03-10 he surrendered 1,396 shares. The reported price for both dispositions is $0.00 and no cash proceeds were recorded, indicating shares were withheld to satisfy tax withholding rather than sold on the open market.

Key Details

• Transaction dates: 2026-03-08 (401 shares) and 2026-03-10 (1,396 shares).
• Reported price: $0.00 per share; reported total value: $0 for each disposition (tax withholding transaction).
• Footnotes: filing notes include restricted stock units — 509,648 RSUs referenced in the 3/8 entry and 503,917 RSUs referenced in the 3/10 entry (these figures reflect RSUs included in beneficial ownership disclosures).
• Filing date: Form 4 filed 2026-03-11. (Form 4s are typically due within two business days of a transaction; review filing timing if timeliness is a concern.)
• These were tax-withholding dispositions (code F), not open-market sales.

Context

• This is a routine tax-withholding action following equity vesting: shares are surrendered to the company to cover required tax withholding. Such disposals do not necessarily indicate a change in an insider’s view of the company since no shares were sold for cash on the market.